FM
ADPT icon

Family Management’s Adaptive Biotechnologies ADPT Stock Holding History

Family Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17,556
Closed -$244K – 177
2022
Q1 		$244K Hold
17,556
– – 0.07% 141
2021
Q4 		$493K Buy
17,556
+2,193
+14% +$67.2K 0.13% 103
2021
Q3 		$522K Buy
15,363
+6,476
+73% +$234K 0.14% 99
2021
Q2 		$363K Buy
+8,887
New +$345K 0.1% 127

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

Family Management's ADPT Position: Q2 2022 in Review

Family Management sold out of Adaptive Biotechnologies (ADPT) in Q2 2022, closing a stake of 17,556 shares — an estimated $244K sold.

Family Management first reported a position in ADPT in Q2 2021 and held it in 4 quarters. The position peaked at $522K in Q3 2021. 209 funds tracked by Wall St. Rank hold ADPT as of Q2 2022.

  • Family Management reported no remaining Adaptive Biotechnologies position as of Q2 2022 after selling out during the quarter.
  • Family Management sold 17,556 Adaptive Biotechnologies shares in Q2 2022, an estimated $244K.
  • Family Management first reported a position in Adaptive Biotechnologies in Q2 2021 and held it in 4 quarters.
  • Family Management's Adaptive Biotechnologies position peaked at $522K in Q3 2021.
  • 209 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2022.

Based on Family Management's 13F filing for Q2 2022, filed 15 Aug 2022.